CareDx Inc
CDNA.O- Latest Trade
- trading higher23.87USD
- Change
- 0
- % Change
0.00%
- Day Range
- -- - --
- 52-Week Range
- 21.25 - 96.88
As of May 26 2022. Values delayed up to 15 minutes
- Previous Close
- 23.87
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 18.35
- Shares Out (Mil)
- 53.22
- Market Cap
- 1,238.99
- Forward P/E
- -57.06
- Dividend Yield
- -99,999.99
Key Statistics
1.57142857 mean rating - 7 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 4.02
- Price To Book (Quarterly)
- 2.70
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -10.18
- Return On Equity (TTM)
- -9.12
2021 (millions USD)
About CareDx Inc
Company Information
CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Address
1 Tower Place, 9Th FloorSOUTH SAN FRANCISCO, CA
94080
United States
Industry
Healthcare Facilities
Executive Leadership
- Michael D. Goldberg
- Independent Chairman of the Board
- Reginald Seeto
- President, Chief Executive Officer, Director
- Ankur Dhingra
- Chief Financial Officer
- Sasha King
- Chief Marketing Officer
- Marcel Konrad
- Vice President, Corporate Controller
- Alexander L. Johnson
- Chief Business Officer and Head of Testing Services
- Peter Maag
- Director
- Arthur A. Torres
- Director
- Hannah A. Valantine
- Director
- George W. Bickerstaff
- Independent Director
- Frederick E. Cohen
- Independent Director
- Grace E. Colon
- Independent Director
- Christine M. Cournoyer
- Independent Director
- William A. Hagstrom
- Independent Director
- Ralph Snyderman
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,841.10 | 0.28%Negative |
| Copper | 770.45 | 1.21%Negative |
| Brent Crude Oil | 117.54 | 3.08%Positive |
| CBOT Soybeans | 1,725.75 | 2.66%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,061.39 | 2.08%Positive |
| Euro STOXX 50 | 3,740.31 | 1.72%Positive |
| FTSE 100 | 7,564.92 | 0.56%Positive |
| Nikkei 225 | 26,604.84 | 0.27%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes